A comparison was made on the tumor growth curves and survival curves for these three models which had been treated with CD8+ T cells (activated by DC/tumor fusion, DC/tumor fusion vaccine+LPS, DC/tumor fusion vaccine+anti-CTLA-4 mAb, DC/tumor fusion vaccine+LPS-CTLA-4 mAb as well as DC/tumor fusion vaccine+LPS‐Nb36), naïve T cells, and PBS, respectively. The gene discussed is CD8A; the disease is neoplasm.